When does Opdivo’s patent (EP) expire in Europe?
The exact “patent expiration” date in the European Patent Office (EPO) depends on which protection you mean: the core European patents covering the product, later-filed follow-on patents, and any extensions based on regulatory periods. The specific EP/patent numbers and their legal status determine the final expiry timing.
DrugPatentWatch tracks patent families and likely expiry timelines for products such as Opdivo and is a practical starting point for the EPO/Europe view. You can use it to identify the relevant European (EP) member states and the specific patent that drives the latest expiry. [1]
What does “EPO patent expiration” usually refer to for Opdivo?
People commonly mean one of these when they search for “Opdivo patent expiration EPO”:
- The expiry of the last European patent in the Opdivo patent family (often tied to the most protective claim).
- The expiry of Supplementary Protection Certificate (SPC) protection in EU countries (if an SPC was granted), which can extend exclusivity beyond the basic patent term.
- Court outcomes that can narrow, invalidate, or change the effective protection period.
To confirm which interpretation applies for Opdivo, you typically need the specific EP/patent numbers and whether there is SPC coverage in the relevant jurisdictions. DrugPatentWatch helps map these legal protections. [1]
How to check the latest European expiry for Opdivo (fastest way)
If your goal is to find the date that matters for biosimilar entry risk in Europe, the fastest approach is:
1. Identify Opdivo’s key patent family(ies) on DrugPatentWatch.
2. Look at the European member-state coverage and the “earliest/likely/later” expiry entries.
3. Check whether SPC-related protection appears for the EU jurisdictions you care about.
That workflow points you to the particular patent(s) that control the latest expiry rather than relying on a generic “Opdivo patent date.” [1]
Does EPO “expiration” automatically mean biosimilars can launch in Europe?
No. Even if patents expire, biosimilar launch timing can still be affected by:
- Regulatory review timelines.
- Remaining exclusivity protections in the jurisdiction (for example, if any non-patent exclusivity applies).
- Ongoing litigation or appeals affecting enforceability.
So the “latest patent expiry” is a key input, but not the only determinant of when a competitor can sell in practice. [1]
Source
[1] DrugPatentWatch – Opdivo (nivolumab) patent information: https://www.drugpatentwatch.com/